Krystal Submits Investigational New Drug (IND) Application for KB103, Topical Gene Therapy Candidate for Dystrophic … – Nasdaq
The Lincolnian Online |
Krystal Submits Investigational New Drug (IND) Application for KB103, Topical Gene Therapy Candidate for Dystrophic …
Nasdaq PITTSBURGH, March 27, 2018 (GLOBE NEWSWIRE) — Krystal Biotech Inc., ("Krystal") (NASDAQ:KRYS), a gene therapy company developing "off-the-shelf" treatments for rare dermatological diseases, announces the submission of an Investigational New Drug (IND … Krystal Biotech (KRYS) Submits IND Application for KB103, Topical … |
